A must read if you are heading to the #AACR25 session on CAR-T Cells in Hematological Malignancies: Innovations and Pitfalls from Kai Rejeski Memorial Sloan Kettering Cancer Center. brnw.ch/21wSePV

Second day of the 10th Heidelberg Myeloma Workshop How to further improve on CAR-Ts? Kai Rejeski Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Prof. Dr. Hermann Einsele Jens Hillengass Jens Lohr #mmsm

#iwCART25 | Kai Rejeski discusses non-relapse mortality in patients receiving CAR T-cells and bispecifics, highlighting the main drivers of NRM: 🎥 ow.ly/p5TA50VRCAW #CARTCell #ImmunoOnc #HemOnc #LYMsm #MMSM #Myeloma #Lymphoma #MultipleMyeloma

📢 New Review Out in Haematologica! Together with Ofrat Beyar Katz and Kai Rejeski, we discuss hematologic toxicities of CAR-T therapy—definitions, mechanisms, and clinical impact. Read the full review 👉 haematologica.org/article/view/1… #CAR_T #Hematology #Toxicity

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Whirlwind day at #EHA25 presenting first on eligibility + longterm safety of CAR-T in 2L LBCL and then receiving this years EHA Publication Award for our ICAHT work in the Presidential Session 🙌 Grateful to share these moments with friends, collaborators and fantastic mentors!

Great work by Yi Lin and team from Mayo Clinic Comprehensive Cancer Center on potential predictors of IEC CNP and Parkinsonism presented at this years #EHA25

What an absolute tour-de-force just published in Cancer Cell by Michael Green, PhD and colleagues ! Using single-nucleus multiome profiling of 232 (!) lymphoma samples, they uncover distinct tumor microenvironmental features, relevant for response to CART19 ☝️

Thanks for shining a light on our recent paper on nonrelapse mortality with bispecifics with this informative commentary - enjoyed reading it Rahul Banerjee, MD, FACP and Sam Yamshon !

Beautiful paper by my good friend Philipp Karschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in Nat Rev Neurology on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇

Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRS and ICANS. Kai Rejeski & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key

#Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in pts getting bispecific antibodies: pubmed.ncbi.nlm.nih.gov/40690761/. #mmsm

Fully support this effort led by Rahul Banerjee, MD, FACP ! Infections = Number 1️⃣ driver of NRM with BsAb. But - We can do something about it and primary IVIG PPX has been shown to reduce mortality in this vulnerable patient collective. #startivig #dontwaitfortheinfection